Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer, and as one of our directors since our inception in 2007. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, a global pharmaceutical company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division; the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly; the Internal Medicine Division; the Lilly Clinic, Lilly’s dedicated Phase 1 unit; and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease. Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. He earned a BA, cum laude, from Yale University and an MD from the University of California, San Diego School of Medicine. Following an internship and residency in Internal Medicine at the University of California, San Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research fellowships in Nephrology at the University of Pennsylvania.
Dr. Bodick is a co-founder and has served as our Chief Medical Officer since our inception in 2007. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for early-phase clinical investigation at Lilly Research Laboratories. Dr. Bodick also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computer-based systems to support image-intensive diagnosis. Dr. Bodick holds 14 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health. Dr. Bodick earned an AB from Cornell University, a PhD in neuroscience from Columbia University, an MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.
Mr. Driscoll has served as our Chief Financial Officer since May 2013. Mr. Driscoll also serves on the Board of Directors of OXiGENE., a biopharmaceutical company. Prior to joining us, Mr. Driscoll was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company since 2009. Previously, Mr. Driscoll also served as Chief Financial Officer from 2007 to 2008, and subsequently Chief Executive Officer from 2008 to 2009, at Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company; Chief Financial Officer at Astraris, Inc., a private biotechnology company, from 2006 to 2007; and Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company, from 2002 to 2006. Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University.
Ms. Willwerth has more than 20 years of experience in pharmaceutical development. She joined Flexion Therapeutics from Viacell, where she was a member of the company’s Executive Management team and served as Vice President, Product Development, with management responsibility for the company’s interdisciplinary cellular therapy and fertility preservation development programs. Ms. Willwerth previously served as Senior Director, Product Development at The Medicines Company, where she focused on cardiovascular therapy clinical and product development. Prior to that, she held a number of ascendant clinical operations positions at Astra Pharmaceuticals and Biopure Corporation. Ms. Willwerth holds a BS in Biology, with high distinction, from Worcester Polytechnic Institute.
Dr. Ballal brings more than 10 years of business and transactional experience to Flexion Therapeutics. Most recently, he was running business development at the Broad Institute where he completed the cancer stem cell transaction that founded Verastem Inc. (VSTM). Prior to the Broad, he worked as an associate at ASM Ventures and participated in their investments that included: A&G Pharmaceuticals, Marligen (sold to Origene), and Quosa (sold to Elsevier). Rahul started his career in Silicon Valley as the founder/CEO of Redmind, a venture backed data analytics startup that he sold to Ikimbo Inc., in 2002. Rahul has a PhD in cancer biology from Georgetown School of Medicine, an MS in bioinformatics from Johns Hopkins, and a BA from Brown University. He also completed his Kauffman Fellowship at Novartis Venture Funds.
Ms. Davidson has more than 20 years of broad corporate finance experience encompassing treasury management, strategic planning, operations finance, and controllership. Most recently, she served as Director of Finance at OmniSonics Medical Technologies, Inc. Prior to that, she served in various finance, strategy and administration positions at Fisher Scientific International, Inc., Pepsi Bottling Group, and PerkinElmer Inc. Ms. Davidson has been involved in a number of M&A transactions, venture debt and equity financing totaling $90 million, and numerous product launches. She holds a BA and an MBA, both from the University of New Hampshire.
Mr. Deardorf has more than 18 years of commercial biopharmaceutical experience encompassing marketing, business development, market development, program management and sales. Most recently, he provided strategic commercial guidance to biopharmaceutical start-up companies as an independent consultant. Prior to that, he spent 14 years at Genzyme Corp. working on a variety of biomaterial, cell-based, and small molecule products in the orthopaedic market. Most notably, Mr. Deardorf was Vice President of Marketing for the Synvisc® franchise and led the extremely successful launch of Synvisc-One, an injectable product for osteoarthritis of the knee. He holds a BS in Biochemistry from California Polytechnic State University and an MBA from the Wharton School at the University of Pennsylvania.
Dr. Doyle has over 20 years of clinical, academic and biopharmaceutical experience. She has held faculty positions at Harvard Medical School, Tulane University School of Medicine and the University of Pennsylvania School of Medicine. Prior to joining Flexion, Dr. Doyle served as Senior Medical Director in Translational Medicine at Alexion Pharmaceuticals focusing on First in Human and Proof of Concept studies in orphan diseases. Prior to her tenure at Alexion, Dr. Doyle held positions of increasing responsibility at Centocor and Janssen R&D where she worked on the successful BLA filing for Golimumab in Rheumatoid Arthritis and served as Clinical lead for the Phase III Ustekinumab Psoriatic arthritis program. She earned her BA, magna cum laude, from Princeton University and her MD, cum laude, from Yale University School of Medicine. Following an internship and residency in Internal Medicine at Massachusetts General Hospital, Dr. Doyle completed clinical and research fellowships in Rheumatology and Immunology at Brigham and Women’s Hospital and Harvard Medical School. She is board certified in Rheumatology and maintains a clinical practice at the Veterans Administration Hospital.
Mr. Leblanc has extensive experience in pharmaceutical development and operations with an emphasis on novel drug delivery systems. Most recently, Mr. Leblanc spent over 4 years as the Director of Pharmaceutical Development at Merck Serono in Geneva, Switzerland, where he was globally responsible for drug product and process development of all large molecule programs throughout the development life cycle. Prior to this, he spent 11 years at Alkermes, Inc. in various positions, specializing in the characterization and development of manufacturing processes for PLGA based drug delivery programs as well as the start-up and operation of Alkermes’ internal manufacturing processes for Nutropin Depot® , Vivitrol® , as well as Risperdal Consta® . He holds a BS degree from Syracuse University in Chemical Engineering and a joint MS from University of Pennsylvania School of Engineering and the Wharton School in Technology Management.
Ms. Lufkin joined Flexion in May 2011 and brings more than 15 years of experience in Clinical Operation including global studies across multiple therapeutic areas. Prior to joining Flexion, Ms. Lufkin served as Director Clinical Operations at Synta Pharmaceuticals where she was responsible for leading two global oncology programs during her 7 year tenure. Previously, she was responsible for overseeing a Phase 3 infectious disease program at Cubist Pharmaceuticals which received regulatory approval by the FDA and also held positions within Clinical Operations at Genetics Institute (currently Pfizer) and Ergo Science. Ms. Lufkin holds a BS in Biology from the University of Massachusetts, Amherst and a Master’s in Public Health with a concentration in Epidemiology and Biostatistics from Boston University.
Ms. Wentworth brings more than 20 years of experience in both domestic and international Regulatory Affairs that spans early and late development across multiple therapeutic areas. Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts for nearly 10 years. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc., where she was responsible for advancing their lead program through Phase 3 development and into the registration phase with FDA and EMA. Ms. Wentworth also held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a BS in pre-veterinary medicine from the University of New Hampshire.